Clinical Trial

Risk Assessment and Syndrome Evolution Models for Chronic Atrophic Gastritis Malignant Transformation

Recruiting
View on ClinicalTrials.gov →
Summary
Chronic atrophic gastritis (CAG) is acknowledged as the precancerous stage of gastric cancer (GC). The present study aims to developed risk assessment and syndrome evolution models of CAG malignant transformation events combining TCM indicators with modern medicine indicators. The proposed study is a registry study based participant survey conducted in 4 hospitals in Beijing, China. After obtaining informed consent, a total of 2000 study patients diagnosed with CAG will be recruited. 10-year follow-ups are carried out on-site in hospitals and off-site by telephone to track malignant transformation events.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2017-08-24; most recent amendment 2020-12-25.
Status change: Not Yet Recruiting → Recruiting 2020-12-25
Trial Details
NCT Number NCT03261934
Lead Sponsor Beijing University of Chinese Medicine
Collaborators: The University of Science and Technology of China, China Academy of Chinese Medical Sciences, Harvard Medical School (HMS and HSDM)
Conditions Risk Assessment of Chronic Atrophic Gastritis Malignant Transformation
Enrollment 2,000 participants
Start Date 2018-01-01
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2020-12-29